EA201692126A1 - Способ достижения безлекарственной ремиссии у субъектов с ранним ревматоидным артритом (ra, ра) - Google Patents

Способ достижения безлекарственной ремиссии у субъектов с ранним ревматоидным артритом (ra, ра)

Info

Publication number
EA201692126A1
EA201692126A1 EA201692126A EA201692126A EA201692126A1 EA 201692126 A1 EA201692126 A1 EA 201692126A1 EA 201692126 A EA201692126 A EA 201692126A EA 201692126 A EA201692126 A EA 201692126A EA 201692126 A1 EA201692126 A1 EA 201692126A1
Authority
EA
Eurasian Patent Office
Prior art keywords
subjects
achievement
medium
early rheumatoid
free remission
Prior art date
Application number
EA201692126A
Other languages
English (en)
Inventor
Четан Кариекар
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201692126A1 publication Critical patent/EA201692126A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)

Abstract

Настоящее изобретение относится к способам и композициям для достижения безлекарственной ремиссии у субъектов с ранним ревматоидным артритом (RA) посредством введения нуждающемуся в этом субъекту эффективного количества растворимого белка CTLA4 до достижения ремиссии, определяемой с помощью калькулятора активности заболевания при ревматоидном артрите (DAS), а затем полную отмену RA терапии.
EA201692126A 2014-04-25 2015-04-23 Способ достижения безлекарственной ремиссии у субъектов с ранним ревматоидным артритом (ra, ра) EA201692126A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984287P 2014-04-25 2014-04-25
PCT/US2015/027281 WO2015164595A1 (en) 2014-04-25 2015-04-23 Use of ctla4 compound for achieving drug-free remission in subjects with early ra

Publications (1)

Publication Number Publication Date
EA201692126A1 true EA201692126A1 (ru) 2017-03-31

Family

ID=53055123

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692126A EA201692126A1 (ru) 2014-04-25 2015-04-23 Способ достижения безлекарственной ремиссии у субъектов с ранним ревматоидным артритом (ra, ра)

Country Status (13)

Country Link
US (2) US20170042972A1 (ru)
EP (1) EP3134109A1 (ru)
JP (1) JP2017513903A (ru)
KR (1) KR20160145789A (ru)
CN (1) CN106456712A (ru)
AU (1) AU2015249656A1 (ru)
BR (1) BR112016023450A2 (ru)
CA (1) CA2947217A1 (ru)
EA (1) EA201692126A1 (ru)
IL (1) IL248421A0 (ru)
MX (1) MX2016013611A (ru)
SG (1) SG11201608848XA (ru)
WO (1) WO2015164595A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
SG10202111207TA (en) 2017-05-24 2021-11-29 Als Therapy Development Inst Therapeutic anti-cd40 ligand antibodies
KR20200074137A (ko) 2017-10-10 2020-06-24 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
WO2019079520A2 (en) 2017-10-18 2019-04-25 Alpine Immune Sciences, Inc. ICOS VARIANT LIGAND IMMUNOMODULATORY IMMUNOMODULATORY PROTEINS, COMPOSITIONS AND METHODS THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MXPA02012603A (es) 2000-07-03 2003-05-14 Squibb Bristol Myers Co Metodos para tratamiento de enfermedades reumaticas utilizando una molecula de ctla4 soluble.
AU2003300276B2 (en) 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
ATE488600T1 (de) 2002-12-23 2010-12-15 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
KR101398713B1 (ko) 2005-12-20 2014-06-12 브리스톨-마이어스 스큅 컴퍼니 조성물 및 조성물의 제조 방법
SG153832A1 (en) 2005-12-20 2009-07-29 Bristol Myers Squibb Co Stable protein formulations
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Also Published As

Publication number Publication date
US20200069772A1 (en) 2020-03-05
WO2015164595A1 (en) 2015-10-29
US20170042972A1 (en) 2017-02-16
SG11201608848XA (en) 2016-11-29
BR112016023450A2 (pt) 2017-10-17
CN106456712A (zh) 2017-02-22
IL248421A0 (en) 2016-11-30
MX2016013611A (es) 2017-02-02
CA2947217A1 (en) 2015-10-29
AU2015249656A1 (en) 2016-11-03
KR20160145789A (ko) 2016-12-20
JP2017513903A (ja) 2017-06-01
EP3134109A1 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
EA201891983A8 (ru) Комбинированная терапия антителами к cd73
EA201790377A1 (ru) Антитела к глюкагону и их применения
EA201990473A1 (ru) Полиглутамированные антифолаты и их применение
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201790530A1 (ru) Агенты, связывающиеся с cd123, и виды их применения
BR112015026122A2 (pt) métodos para usar interleucina-10 para tratar doenças e desordens
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
EA201591762A1 (ru) Человеческие антитела к grem1
EA201692126A1 (ru) Способ достижения безлекарственной ремиссии у субъектов с ранним ревматоидным артритом (ra, ра)
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
EA201591839A1 (ru) Терапевтические пептиды
EA201591973A1 (ru) Антитела человека, связывающиеся с g-белком rsv
EA202091360A1 (ru) Гуманизированные анти-liv1 антитела для лечения рака молочной железы
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
MX2020009879A (es) Anticuerpos anti-il-27 y sus usos.
EA201790563A1 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
EA202190094A1 (ru) Антитела против cd40 для применения в лечении аутоиммунного заболевания
EA202191666A1 (ru) Антитела к il-27 и их применение